Single-cell profiling in ovarian germ cell and sex cord-stromal tumours
- PMID: 40269311
- PMCID: PMC12152133
- DOI: 10.1038/s41416-025-03012-6
Single-cell profiling in ovarian germ cell and sex cord-stromal tumours
Abstract
Background: The tumour microenvironment of rare ovarian germ cell tumours (OGCT) and sex-cord stromal tumours (SCST) remains unexplored. To better understand their immune and stromal landscape, we constructed a blueprint using single-cell RNA sequencing (scRNA-seq).
Methods: We performed scRNA-seq of 66, 919 cells from twelve fresh tumour samples: seven adult granulosa cell tumour (aGSCT), one juvenile GSCT (jGSCT), one Sertoli-Leydig (SL) tumour, two immature teratoma (IT) and one dysgerminoma (DG). We characterised immune cell subtypes and fibroblasts based on their specific marker genes. Validation included combined positive score (CPS) of 46 OGCTs and 66 SCSTs, and bulk RNA sequencing (n = 32).
Results: Cell clustering and annotation revealed a immune-activated microenvironment in DG, driven by PD-1- exhausted T cells, reflected in high CPS (≥10) and upregulated immune pathways. IT samples displayed no immunoreactive profile, consistent with a negative CPS. aGSCTs exhibited a fibroblast-enriched, immune-desert phenotype, with low T cell infiltration and increased immunosuppressive LYVE1 and CX3CR1+ macrophages, corresponding to negative CPS.
Conclusion: We constructed a detailed blueprint of the OGCT and SCSTs microenvironment of, elucidating potential modulators that shape their immune landscape. The immune-suppressive environment in aGSCTs likely limits immunotherapy response, as immunosuppressive macrophages inhibit T cell expansion along with EMT activation and fibroblast predominance.
© 2025. The Author(s), under exclusive licence to Springer Nature Limited.
Conflict of interest statement
Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: The ethical committee of the University Hospitals Leuven approved this study (s64996), and written informed consent was obtained from all patients. The study was conducted in accordance with the principles outlined in the Declaration of Helsinki.
Similar articles
-
Integrative analysis of T cell-associated markers in Ewing sarcoma reveals prognostic signatures and immune dynamics.Front Immunol. 2025 Jun 18;16:1586544. doi: 10.3389/fimmu.2025.1586544. eCollection 2025. Front Immunol. 2025. PMID: 40607387 Free PMC article.
-
Systematic screening of metabolic pathways to identify two breast cancer subtypes with divergent immune characteristics.Sci Rep. 2025 Jul 1;15(1):20996. doi: 10.1038/s41598-025-05179-7. Sci Rep. 2025. PMID: 40594370 Free PMC article.
-
Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses.Cochrane Database Syst Rev. 2016 Mar 1;3(3):CD010360. doi: 10.1002/14651858.CD010360.pub2. Cochrane Database Syst Rev. 2016. PMID: 26930463 Free PMC article.
-
Attenuated immune surveillance during squamous cell transformation of pancreatic adenosquamous cancer defines new therapeutic opportunity for cancer interception.J Immunother Cancer. 2025 Jun 23;13(6):e012066. doi: 10.1136/jitc-2025-012066. J Immunother Cancer. 2025. PMID: 40550564 Free PMC article.
-
Chemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent disease.Cochrane Database Syst Rev. 2011 Mar 16;2011(3):CD007584. doi: 10.1002/14651858.CD007584.pub2. Cochrane Database Syst Rev. 2011. PMID: 21412906 Free PMC article.
Cited by
-
In silico and in vitro assessment of TP53, ATM, RAD51, and BAX genes in gastric cancer and their contribution to radiotherapy resistance.Hereditas. 2025 Jul 12;162(1):125. doi: 10.1186/s41065-025-00496-3. Hereditas. 2025. PMID: 40652278 Free PMC article.
References
-
- Van Nieuwenhuysen E, Lambrechts S, Lambrechts D, Leunen K, Amant F, Vergote I. Genetic changes in nonepithelial ovarian cancer. Expert Rev Anticancer Ther. 2013;13:871–82. - PubMed
-
- Laga T, Vergote I, Van Nieuwenhuysen E. Immunotherapy in rare ovarian cancer. Curr Opin Oncol. 2021;33:447–56. - PubMed
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous